The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.5K Targets. Of those, 1.4M data for 679K Compounds and 4.6K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

10 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.EBI
Wroclaw University of Technology
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI
University of Florida
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI
University of Athens
Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.EBI
Genentech
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.EBI
University of Arkansas For Medical Sciences
Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.EBI
Aventis Pharma Deutschland
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.EBI
University of Athens
Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.EBI
Cea
Novel benzimidazole-pyrimidine conjugates as potent antitumor agents.EBI
National Research Centre
Synthesis of potent antitumor and antiviral benzofuran derivatives.EBI
National Research Centre